Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.47
-0.0200-0.31%
Post-market: 6.500.0300+0.46%18:52 EDT
Volume:1.64M
Turnover:10.54M
Market Cap:560.14M
PE:-3.20
High:6.61
Open:6.23
Low:6.20
Close:6.49
Loading ...

Analysts supportive of Kura/Kirin deal despite major selloff in shares

seekingalpha
·
22 Nov 2024

BUZZ-Kura slides as licensing deal seen as reducing chances of buyout

Reuters
·
21 Nov 2024

Kura Oncology price target lowered to $18 from $22 at Scotiabank

TIPRANKS
·
21 Nov 2024

Kura Oncology Shares Fall 26.5% After Co to Partner With Kyowa Kirin for Blood Cancer Therapy

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk

Dow Jones
·
21 Nov 2024

Kura Oncology price target lowered to $34 from $37 at Wedbush

TIPRANKS
·
21 Nov 2024

Strategic Collaboration and Financial Strength Underscore Buy Rating for Kura Oncology

TIPRANKS
·
21 Nov 2024

Strategic Partnership with Kyowa Kirin Positions Kura Oncology for Leadership in AML Menin Inhibitor Market

TIPRANKS
·
21 Nov 2024

BUZZ-Kura to partner with Kyowa Kirin for blood cancer drug; shares fall

Reuters
·
21 Nov 2024

Kura Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024

Wedbush Lowers Price Target on Kura Oncology to $34 From $37, Keeps Outperform Rating

MT Newswires Live
·
21 Nov 2024

Kura Oncology Inc : H.c. Wainwright Raises Target Price to $37 From $32

THOMSON REUTERS
·
21 Nov 2024

Strategic Partnerships and Growth Potential Drive Buy Rating for Kura Oncology

TIPRANKS
·
21 Nov 2024

Kura Oncology Shares Fall 12% Premarket After Co to Partner With Kyowa Kirin for Blood Cancer Therapy

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology Inc : Jefferies Cuts Target Price to $28 From $32

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration

Dow Jones
·
21 Nov 2024

Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug

MT Newswires Live
·
21 Nov 2024

Kura Oncology Shares Extend After the Bell Losses, Last Down 15% at $13.50

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Reuters
·
21 Nov 2024

Kura Oncology Shares Down 0.7% at $15.80 in Choppy Trading After the Bell Following Collaboration With Yowa Kirin to Develop Ziftomenib for Acute Leukemias

THOMSON REUTERS
·
21 Nov 2024